DE69001686T2 - Behandlung von leukozytstoerungen mit gm-csf. - Google Patents

Behandlung von leukozytstoerungen mit gm-csf.

Info

Publication number
DE69001686T2
DE69001686T2 DE9090300840T DE69001686T DE69001686T2 DE 69001686 T2 DE69001686 T2 DE 69001686T2 DE 9090300840 T DE9090300840 T DE 9090300840T DE 69001686 T DE69001686 T DE 69001686T DE 69001686 T2 DE69001686 T2 DE 69001686T2
Authority
DE
Germany
Prior art keywords
csf
treating
dysfunction
leucocytic
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE9090300840T
Other languages
English (en)
Other versions
DE69001686D1 (de
Inventor
Eric M Bonnem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE69001686D1 publication Critical patent/DE69001686D1/de
Publication of DE69001686T2 publication Critical patent/DE69001686T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE9090300840T 1989-01-30 1990-01-26 Behandlung von leukozytstoerungen mit gm-csf. Expired - Fee Related DE69001686T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30439189A 1989-01-30 1989-01-30

Publications (2)

Publication Number Publication Date
DE69001686D1 DE69001686D1 (de) 1993-07-01
DE69001686T2 true DE69001686T2 (de) 1993-09-02

Family

ID=23176323

Family Applications (1)

Application Number Title Priority Date Filing Date
DE9090300840T Expired - Fee Related DE69001686T2 (de) 1989-01-30 1990-01-26 Behandlung von leukozytstoerungen mit gm-csf.

Country Status (21)

Country Link
US (1) US5178855A (de)
EP (2) EP0455726A1 (de)
JP (1) JPH0651640B2 (de)
KR (1) KR0137361B1 (de)
AT (1) ATE89737T1 (de)
AU (1) AU633054B2 (de)
CA (1) CA2045605C (de)
DE (1) DE69001686T2 (de)
DK (1) DK0382381T3 (de)
ES (1) ES2055314T3 (de)
FI (1) FI913625A0 (de)
HK (1) HK46196A (de)
HU (1) HU207229B (de)
IE (1) IE64234B1 (de)
IL (1) IL93219A (de)
MY (1) MY105798A (de)
NZ (1) NZ243953A (de)
OA (1) OA09509A (de)
PT (1) PT92995B (de)
WO (1) WO1990008554A1 (de)
ZA (1) ZA90600B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1462392A (en) * 1991-02-22 1992-09-15 Amgen, Inc. Use of gm-csf and g-csf to promote accelerated wound healing
GB9120304D0 (en) * 1991-09-24 1991-11-06 Erba Carlo Spa Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
WO1994028919A1 (en) * 1993-06-08 1994-12-22 Ajinomoto Co., Inc. Hematopoietic cell proliferation accelerator
EP0791061A4 (de) * 1994-03-04 1998-07-15 Ludwig Inst Cancer Res Tiere mit gezielter genunterbrechung
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
JP2010513525A (ja) * 2006-12-22 2010-04-30 ノヴァデル ファーマ インコーポレイテッド 安定な抗嘔吐経口噴霧製剤および方法
US7697268B2 (en) * 2007-08-09 2010-04-13 Haworth, Inc. Modular electrical distribution system for a building

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
WO1987002060A1 (en) * 1985-10-03 1987-04-09 Biogen N.V. Human granulocyte-macrophage colony stimulating factor-like polypeptides and processes for producing them in high yields in microbial cells
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
DE3686582T2 (de) * 1985-11-27 1993-01-28 Genetics Inst Behandlung einer krankheit vom aids-typ.
HU212277B (en) * 1986-05-06 1996-04-29 Genetics Inst Process for producing m-csf
US5162111A (en) * 1986-07-30 1992-11-10 Grabstein Kenneth H Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
EP0276846A3 (de) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Derivate des koloniestimulierenden Faktors
WO1989004173A1 (en) * 1987-11-12 1989-05-18 Schering Corporation Acceleration of bone formation with gm-csf

Also Published As

Publication number Publication date
IL93219A0 (en) 1990-11-05
WO1990008554A1 (en) 1990-08-09
JPH0651640B2 (ja) 1994-07-06
CA2045605C (en) 1997-02-11
US5178855A (en) 1993-01-12
EP0455726A1 (de) 1991-11-13
NZ243953A (en) 1997-06-24
HK46196A (en) 1996-03-22
ES2055314T3 (es) 1994-08-16
KR0137361B1 (ko) 1998-04-25
IE64234B1 (en) 1995-07-26
HUT57607A (en) 1991-12-30
MY105798A (en) 1995-01-30
ZA90600B (en) 1990-10-31
OA09509A (en) 1992-11-15
PT92995A (pt) 1990-07-31
DK0382381T3 (da) 1993-07-12
KR910700069A (ko) 1991-03-13
FI913625A0 (fi) 1991-07-30
EP0382381A1 (de) 1990-08-16
PT92995B (pt) 1995-12-29
IE900318L (en) 1990-07-30
JPH03504980A (ja) 1991-10-31
EP0382381B1 (de) 1993-05-26
AU5048890A (en) 1990-08-24
CA2045605A1 (en) 1990-07-31
ATE89737T1 (de) 1993-06-15
AU633054B2 (en) 1993-01-21
HU207229B (en) 1993-03-29
IL93219A (en) 1998-12-27
DE69001686D1 (de) 1993-07-01

Similar Documents

Publication Publication Date Title
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
DE69527966T2 (de) Pharmazeutische zubereitung für die subkutane, intramuskuläre oder intradermale verabreichung von faktor viii
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE69233760D1 (de) Inhibitoren der menschlichen Elastase von Neutrophilen
ATE158182T1 (de) Arzneimittel sowie deren herstellung und deren verwendung bei der bekämpfung von schmerzen und/oder entzündungen an tieren und menschen
DE69001686D1 (de) Behandlung von leukozytstoerungen mit gm-csf.
ATE81984T1 (de) Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.
GR3015765T3 (en) A novel thrombomodulin-like glycoprotein obtainable from urine.
KR890001580A (ko) B형 간염 바이러스에 의해 유발되는 염증 질환을 치료하는 이중가닥 rna를 함유하는 약물
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
DE3750248T2 (de) Zubereitung und Behandlung der Haut mit Human-Leukocyten-Interferon.
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
IT1246050B (it) Impiego dell'eptastigmina nella terapia dell'ictus cerebrale.
周荣兴 et al. THE EFFECT OF ACUPUNCTURE ON THE PHAGOCYTIC ACTIVITY OF HUMAN LEUKOCYTES
IT9041714A0 (it) Linfa del libro dell'abete rosso (abies picea) per la cura di malattie neoplastiche e da virus in genere
HU900202D0 (en) Process for manufacturing of pharmaceutical compositions comprising gamma-interferon suitable to treatment of ovarion cancer
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee